Connor, Clark & Lunn Investment Management (CC&L)
NGNE icon

Connor, Clark & Lunn Investment Management (CC&L)’s Neurogene NGNE Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-3,962
Closed -$1.31M – 1056
2020
Q2 		$1.31M Buy
3,962
+599
+18% +$156K 0.01% 547
2020
Q1 		$765K Buy
+3,363
New +$692K 0.01% 615

Other funds holding NGNE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s NGNE Position: Q3 2020 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Neurogene (NGNE) in Q3 2020, closing a stake of 3,962 shares — an estimated $1.31M sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in NGNE in Q1 2020 and held it in 2 quarters. The position peaked at $1.31M in Q2 2020. 81 funds tracked by Wall St. Rank hold NGNE as of Q3 2020.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Neurogene position as of Q3 2020 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 3,962 Neurogene shares in Q3 2020, an estimated $1.31M.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Neurogene in Q1 2020 and held it in 2 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Neurogene position peaked at $1.31M in Q2 2020.
  • 81 funds tracked by Wall St. Rank held Neurogene as of Q3 2020.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q3 2020, filed 12 Nov 2020.